Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development
© 2017 Future Medicine Ltd.Heart failure still has a significant disease burden with poor outcomes worldwide despite advances in therapy. The standard therapies have been focused on blockade of renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors, angiotensin receptor b...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/51401 |
| _version_ | 1848758689102561280 |
|---|---|
| author | Hua, Y. Wang, I. Liu, B. Kelly, D. Reid, Christopher Liew, D. Zhou, Y. Wang, B. |
| author_facet | Hua, Y. Wang, I. Liu, B. Kelly, D. Reid, Christopher Liew, D. Zhou, Y. Wang, B. |
| author_sort | Hua, Y. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2017 Future Medicine Ltd.Heart failure still has a significant disease burden with poor outcomes worldwide despite advances in therapy. The standard therapies have been focused on blockade of renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and mineralocorticoid antagonists and the sympathetic nervous system with ß-blockers. The natriuretic peptide system is a potential counter-regulatory system that promotes vasodilatation and natriuresis. Angiotensin receptor neprilysin inhibitors are a new class drug capable of blocking the renin-angiotensin-aldosterone system and enhancing the natriuretic peptide system to improve neurohormonal balance. The success of the PARADIGM-HF trial with LCZ696 and its approval for heart failure treatment is likely to generate a paradigm shift. This review summarises the current knowledge of LCZ696 with a focus on pharmacology, pharmacokinetics and pharmacodynamics, mechanisms of action, clinical efficacy and safety. |
| first_indexed | 2025-11-14T09:47:58Z |
| format | Journal Article |
| id | curtin-20.500.11937-51401 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T09:47:58Z |
| publishDate | 2017 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-514012017-09-13T15:35:35Z Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development Hua, Y. Wang, I. Liu, B. Kelly, D. Reid, Christopher Liew, D. Zhou, Y. Wang, B. © 2017 Future Medicine Ltd.Heart failure still has a significant disease burden with poor outcomes worldwide despite advances in therapy. The standard therapies have been focused on blockade of renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and mineralocorticoid antagonists and the sympathetic nervous system with ß-blockers. The natriuretic peptide system is a potential counter-regulatory system that promotes vasodilatation and natriuresis. Angiotensin receptor neprilysin inhibitors are a new class drug capable of blocking the renin-angiotensin-aldosterone system and enhancing the natriuretic peptide system to improve neurohormonal balance. The success of the PARADIGM-HF trial with LCZ696 and its approval for heart failure treatment is likely to generate a paradigm shift. This review summarises the current knowledge of LCZ696 with a focus on pharmacology, pharmacokinetics and pharmacodynamics, mechanisms of action, clinical efficacy and safety. 2017 Journal Article http://hdl.handle.net/20.500.11937/51401 10.2217/fca-2016-0057 restricted |
| spellingShingle | Hua, Y. Wang, I. Liu, B. Kelly, D. Reid, Christopher Liew, D. Zhou, Y. Wang, B. Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development |
| title | Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development |
| title_full | Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development |
| title_fullStr | Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development |
| title_full_unstemmed | Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development |
| title_short | Angiotensin receptor neprilysin inhibitor LCZ696: Pharmacology, pharmacokinetics and clinical development |
| title_sort | angiotensin receptor neprilysin inhibitor lcz696: pharmacology, pharmacokinetics and clinical development |
| url | http://hdl.handle.net/20.500.11937/51401 |